Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Market Movers
TipRanks 50 Index
AI Stocks
Largest Companies by Market Cap
ETFs
Top ETFs by Upside
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Ideas
Plans
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Trump Dashboard
New
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Economic Indicators
Inflation Rate
Unemployment Rate
Class Actions
Tools
Plans
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Screeners
Plans
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Dividends
Plans
My Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Experts
Plans
Portfolio
Plans
Trending News
More News >
News
Plans
Enterprise Solutions
Plans
Education
Personal Finance
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Advertise with Us
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
More
Plans
Plans & Pricing
Plans
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Screeners
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Research Tools
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Calculators
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividends
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Market Movers
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
More
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Log Out
Advertisement
Advertisement
NAMS
Stock Latest News
Company Announcements
NewAmsterdam Pharma’s Latest Study: A Game Changer for Metabolic Disorders?
3d ago
NAMS
Premium
Company Announcements
NewAmsterdam Pharma’s Antioxidant Study: A Potential Game Changer?
3d ago
NAMS
Premium
Company Announcements
NewAmsterdam Pharma’s VINCENT Study: A Promising Step in Cardiovascular Treatment
3d ago
NAMS
Premium
Company Announcements
NewAmsterdam Pharma’s REMBRANDT Trial: A Potential Game-Changer in Cardiovascular Treatment
3d ago
NAMS
Premium
Ratings
Analyst Recommends Buy on NewAmsterdam Pharma for Promising CETPi Obicetrapib
11d ago
NAMS
Premium
The Fly
NewAmsterdam Pharma assumed with a Buy at H.C. Wainwright
11d ago
NAMS
Premium
The Fly
NewAmsterdam Pharma price target raised to $50 from $42 at Citi
14d ago
NAMS
Premium
Company Announcements
NewAmsterdam Pharma Highlights Progress in Obicetrapib Trials
2M ago
8K
NAMS
Premium
The Fly
NewAmsterdam Pharma initiated with an Overweight at Wells Fargo
2M ago
NAMS
Premium
Company Announcements
NewAmsterdam Pharma’s EMA Validation for Obicetrapib
2M ago
8K
NAMS
Premium
The Fly
NewAmsterdam announces acceptance of MAA for review by EMA for obicetrapib
2M ago
NAMS
Premium
Company Announcements
NewAmsterdam Pharma Signs Supply Agreement with Menarini
3M ago
8K
NAMS
Premium
Ratings
Promising Future for NewAmsterdam Pharma: Buy Rating Backed by Strong Financials and Positive Trial Data
3M ago
NAMS
Premium
Company Announcements
NewAmsterdam Pharma Reports Q2 2025 Financial Results
3M ago
NAMS
Premium
Ratings
Promising Developments and Strong Financial Position Support Buy Rating for NewAmsterdam Pharma
3M ago
NAMS
Premium
Ratings
Buy Rating for NewAmsterdam Pharma Driven by Promising Trial Developments and Strategic Advancements
3M ago
NAMS
Premium
Ratings
Optimistic Buy Rating for NewAmsterdam Pharma Driven by Promising Cardiometabolic Drug Developments
3M ago
NAMS
Premium
The Fly
NewAmsterdam Pharma reports Q2 revenue $19.145M vs $2.279M last year
3M ago
NAMS
Premium
Ratings
Buy Rating for NewAmsterdam Pharma: Promising Developments in Alzheimer’s and Cardiovascular Trials
3M ago
NAMS
Premium
Ratings
Promising Alzheimer’s Biomarker Data and Expert Enthusiasm Drive Buy Rating for NewAmsterdam Pharma
3M ago
NAMS
Premium
Company Announcements
NewAmsterdam Pharma’s Promising Phase 3 Alzheimer’s Trial Results
3M ago
8K
NAMS
Premium
The Fly
NewAmsterdam Pharma presents data from BROADWAY trial at AAIC
3M ago
NAMS
Show More
Trending
Indices
Stocks
ETFs
Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >
You need to enable JavaScript to run this app.
